NCT04971226 2026-03-10
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
Clinical Trials
7 trialsNCT03079505 2019-01-23
DANIN
Hamad Medical Corporation
Phase 3 Terminated
NCT00481247 2017-02-15
DASISION
Bristol-Myers Squibb
Phase 3 Completed
NCT00744497 2016-10-17
READY
Bristol-Myers Squibb
Phase 3 Completed
NCT00123474 2016-08-25
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
Bristol-Myers Squibb
Phase 3 Completed
NCT00123487 2014-11-03
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
Bristol-Myers Squibb
Phase 3 Completed
NCT00362466 2009-11-20
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
Bristol-Myers Squibb
Phase 3 Terminated